Franciosi Consulting Investigating Beta-Adrenergic Receptor Antagonists as Potential New Treatments for Essential Tremor VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. will be performing structure activity analyses of published beta-adrenergic receptor antagonists (a.k.a. beta...

Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021 BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for...

Cala Health Enrolls First Patients in Landmark PROSPECT Study for Essential Tremor BURLINGAME, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Cala Health, Inc, a neuromodulation platform company developing wearable therapies for chronic disease, today announced that the first patients...